Hubei Jumpcan Pharmaceutical Co Ltd (SHG:600566) — Market Cap & Net Worth
Market Cap & Net Worth: Hubei Jumpcan Pharmaceutical Co Ltd (600566)
Hubei Jumpcan Pharmaceutical Co Ltd (SHG:600566) has a market capitalization of $3.65 Billion (CN¥24.97 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #4349 globally and #675 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Jumpcan Pharmaceutical Co Ltd's stock price CN¥27.09 by its total outstanding shares 921662260 (921.66 Million). See Hubei Jumpcan Pharmaceutical Co Ltd capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Hubei Jumpcan Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Hubei Jumpcan Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $2.92 Billion to $3.65 Billion (3.53% CAGR).
Hubei Jumpcan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Jumpcan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.57x
Hubei Jumpcan Pharmaceutical Co Ltd's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.00x
Hubei Jumpcan Pharmaceutical Co Ltd's market cap is 2.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.39 Billion | $4.68 Billion | $934.18 Million | 0.73x | 3.63x |
| 2017 | $4.23 Billion | $5.64 Billion | $1.22 Billion | 0.75x | 3.46x |
| 2018 | $3.79 Billion | $7.21 Billion | $1.69 Billion | 0.53x | 2.25x |
| 2019 | $2.84 Billion | $6.94 Billion | $1.62 Billion | 0.41x | 1.75x |
| 2020 | $2.51 Billion | $6.16 Billion | $1.28 Billion | 0.41x | 1.96x |
| 2021 | $3.60 Billion | $7.63 Billion | $1.72 Billion | 0.47x | 2.09x |
| 2022 | $3.56 Billion | $9.00 Billion | $2.17 Billion | 0.40x | 1.64x |
| 2023 | $4.24 Billion | $9.65 Billion | $2.82 Billion | 0.44x | 1.50x |
| 2024 | $3.92 Billion | $8.02 Billion | $2.53 Billion | 0.49x | 1.55x |
| 2025 | $3.55 Billion | $6.22 Billion | $1.78 Billion | 0.57x | 2.00x |
Competitor Companies of 600566 by Market Capitalization
Companies near Hubei Jumpcan Pharmaceutical Co Ltd in the global market cap rankings as of August 7, 2026.
Key companies related to Hubei Jumpcan Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #556 globally with a market cap of $48.64 Billion USD ( CN¥332.41 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.91 |
| #556 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.64 Billion | CN¥52.11 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Hubei Jumpcan Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hubei Jumpcan Pharmaceutical Co Ltd's market cap moved from $2.92 Billion to $ 3.65 Billion, with a yearly change of 3.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.65 Billion | +3.00% |
| 2025 | CN¥3.55 Billion | -9.56% |
| 2024 | CN¥3.92 Billion | -7.48% |
| 2023 | CN¥4.24 Billion | +19.07% |
| 2022 | CN¥3.56 Billion | -1.11% |
| 2021 | CN¥3.60 Billion | +43.44% |
| 2020 | CN¥2.51 Billion | -11.50% |
| 2019 | CN¥2.84 Billion | -25.19% |
| 2018 | CN¥3.79 Billion | -10.42% |
| 2017 | CN¥4.23 Billion | +24.64% |
| 2016 | CN¥3.39 Billion | +16.29% |
| 2015 | CN¥2.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Hubei Jumpcan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.65 Billion USD |
| MoneyControl | $3.65 Billion USD |
| MarketWatch | $3.65 Billion USD |
| marketcap.company | $3.65 Billion USD |
| Reuters | $3.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more